Asian Annals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ahmad A Amirghofran
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peiravian, F.
Right arrow Articles by Kolaee, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peiravian, F.
Right arrow Articles by Kolaee, S.
Related Collections
Right arrow Cardiac - pharmacology
Asian Cardiovasc Thorac Ann 2007;15:113-117
© 2007 Asia Publishing EXchange Ltd


ORIGINAL CONTRIBUTIONS

Oral Sildenafil to Control Pulmonary Hypertension after Congenital Heart Surgery

Farah Peiravian, MD, Ahmad A Amirghofran, MD1, Mohammad Borzouee, MD1, Gholam H Ajami, MD1, Mohammad R Sabri, MD1, Sara Kolaee, MD

Department of Pediatric Cardiac Surgery, Dena Hospital Kazerun Islamic Azad, University Faculty of Medicine
1 Department of Pediatric Cardiac Surgery and Cardiology, Faghihi Hospital Shiraz University of Medical Sciences, Shiraz, Iran

For reprint information contact: Farah Peiravian, MD Tel: 98 711 624 9134 Fax: 98 711 635 1218 Email: fpeiravian{at}hotmail.com, Department of Pediatric Cardiac Surgery, Dena Hospital, Sattar Khan Street, Shiraz, Iran.

This study investigates the role of oral sildenafil in decreasing pulmonary pressure after congenital heart surgery. Between September 2002 and September 2004, among a group of postoperative children with large septal defects, moderate to severe pulmonary hypertension [pulmonary artery (PA) to aortic (Ao) pressure ratio of 0.76 ± 0.17] and systemic desaturation (Ao Sat = 0.89 ± 0.11), oral sildenafil (0.3 mg·kg–1, every 3 hours) was administered for a period of 24–48 hours (sildenafil group). These patients were compared to a group of 22 children with similar pathologies who did not receive sildenafil (control group). Postoperative PA pressure (28.61 ± 7.80 vs 39.40 ± 10.80 mm Hg) and PA/Ao pressure (0.28 ± 0.08 vs 0.41 ± 0.11) were significantly lower in the sildenafil group ( p = 0.001 and 0.001 respectively). Pulmonary hypertensive crisis was detected in 4 patients in the control group, but none in the sildenafil group ( p = 0.02). There was no significant rise in PA pressure following discontinuation of the drug (26.30 ± 6.66 vs 28.49 ± 10.93 mm Hg, p = 0.366). No significant complications were noticed regarding sildenafil use. Low doses of oral sildenafil appear to be effective and safe to control postoperative PA pressure in children. Absence of rebound pulmonary hypertension, availability, and low cost of the drug are considered as its major advantages.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by SAGE Publications